FSSAI files three adjudication applications against Nestlé India
India’s food regulator has filed three applications alleging food-safety non-compliance across three infant nutrition products, including biotin-level concerns and prohibited promotional claims.
What happened
FSSAI has filed three adjudication applications against Nestle India over alleged food-safety non-compliance involving three infant nutrition products,
Key facts
- 3 separate adjudication applications
- 3 infant nutrition products
Why this matters
Any partnership, acquisition or diligence involving Nestlé India’s infant-nutrition assets should assess the scope of the alleged compliance gaps, potential penalties and required corrective actions.
What to watch
- FSSAI disclosure of the specific products, batches, test results, alleged biotin deviations and prohibited claims.
- Any interim direction involving recalls, stop-sale orders, relabeling, advertising restrictions or sampling expansion.
- Nestlé India's exchange filing, investor call commentary, provisions, product availability updates or change in sales guidance.
- Retailer, pharmacy-chain, e-commerce and hospital-channel actions affecting infant nutrition assortment or visibility.
- Follow-on complaints, consumer litigation, parliamentary attention or scrutiny of other infant formula and pediatric nutrition brands.
- Changes in infant nutrition category sales, search sentiment, social-media discussion and competitor promotional activity.
- Issue a detailed compliance response distinguishing biotin specifications, product batches and the basis for promotional claims.
- Engage FSSAI on product testing, labeling evidence and corrective-action timelines while preparing appeals or adjudication defenses.
- Conduct precautionary internal audits across infant nutrition formulations, labels, healthcare-professional materials and distributor communications.
- Tighten retailer, pharmacy and consumer-service messaging to prevent misinformation and manage potential pullback in high-sensitivity channels.
- Accelerate third-party quality validation and publish limited assurance disclosures if legally and commercially appropriate.